
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% […]







